Literature DB >> 28238240

Altered Plasma MicroRNA Expression in Patients with Mitral Chordae Tendineae Rupture.

Mehmet Bulent Vatan1, Aysel Kalaycı Yigin2, Ramazan Akdemir3, Mustafa Tarik Agac3, Mehmet Akif Cakar3, Murat Aksoy3, Ersan Tatli3, Harun Kilic3, Huseyin Gunduz3, Derya Guzel4, Keziban Karacan5.   

Abstract

BACKGROUND: Mitral chordae tendineae rupture (MCTR) is a progressive disorder which leads to severe mitral regurgitation. Despite its importance, the precise pathogenetic mechanism of MCTR remains unclear. The study aim was to investigate the expression profile of circulating microRNAs (miRNAs) as being potentially involved in the development of MCTR.
METHODS: Twenty-one patients with 'primary' MCTR, and 30 age- and gender-matched controls, were enrolled in the study. Comparisons were made between the expression levels of circulating miRNAs in MCTR patients and controls. Four target gene databases were used to predict target genes and pathways of differentially expressed miRNAs.
RESULTS: Compared to controls, the expression of 22 miRNAs (hsa-miR-106b-5p, hsa-miR-126-3p, hsa-miR-150-5p, hsa-miR-17-5p, hsa-miR-195-5p, hsa-miR-19a-3p, hsa-miR-19b-3p, hsa-miR-20a-5p, hsa-miR-21-5p, hsa-miR-222-3p, hsa-miR-223-3p, hsa-miR-23a-3p, hsa-miR-25-3p, hsa-miR-92a-3p, hsa-miR-93-5p, hsa-miR-26b-5p, hsa-miR-30e-5p, hsa-miR-373-3p, hsa-miR-15b-5p, hsa-miR-16-5p, hsa-miR-191-5p, hsa-miR-26a-5p) were significantly down-regulated in the MCTR group. Bioinformatic analysis indicated that the following potential miRNA targets and pathways are commonly related to the development of MCTR: MMPs, TIMP-2,TGFBR2, VEGFA, PIK3R2, NRAS, PPP3CA, PPP3R1, PTGS 2 were predicted as putative targets of 13 of these miRNAs.
CONCLUSIONS: The present study is the first to describe altered miRNA expression in patients with MCTR. Bioinformatic analysis has revealed that target genes involved in MCTR development were regulated by miRNAs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28238240

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  6 in total

1.  CircRNA TGFBR2/MiR-25-3p/TWIST1 axis regulates osteoblast differentiation of human aortic valve interstitial cells.

Authors:  Cheng Yu; Dannan Wu; Chong Zhao; Chaoguang Wu
Journal:  J Bone Miner Metab       Date:  2020-10-18       Impact factor: 2.626

2.  Clinical value of miR-191-5p in predicting the neurological outcome after out-of-hospital cardiac arrest.

Authors:  Jie Yu; Aihua Zhou; Ying Li
Journal:  Ir J Med Sci       Date:  2021-08-30       Impact factor: 2.089

3.  Putative Circulating MicroRNAs Are Able to Identify Patients with Mitral Valve Prolapse and Severe Regurgitation.

Authors:  Paola Songia; Mattia Chiesa; Valentina Alfieri; Ilaria Massaiu; Donato Moschetta; Veronika Myasoedova; Vincenza Valerio; Laura Fusini; Paola Gripari; Marco Zanobini; Paolo Poggio
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 5.923

4.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

5.  Circulating miRNA Expression Profiling in Primary Aldosteronism.

Authors:  Abel Decmann; Gábor Nyírö; Ottó Darvasi; Péter Turai; Irina Bancos; Ravinder Jeet Kaur; Raffaele Pezzani; Maurizio Iacobone; Ivana Kraljevic; Darko Kastelan; Mirko Parasiliti-Caprino; Mauro Maccario; Nina Nirschl; Daniel Heinrich; Martin Reincke; Attila Patócs; Peter Igaz
Journal:  Front Endocrinol (Lausanne)       Date:  2019-10-29       Impact factor: 5.555

Review 6.  MicroRNAs in Valvular Heart Diseases: Biological Regulators, Prognostic Markers and Therapeutical Targets.

Authors:  Francesco Nappi; Adelaide Iervolino; Sanjeet Singh Avtaar Singh; Massimo Chello
Journal:  Int J Mol Sci       Date:  2021-11-09       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.